{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:39:39Z","timestamp":1793155179125,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.ejca.2017.03.019","type":"journal-article","created":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T03:15:54Z","timestamp":1493090154000},"page":"133-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer"],"prefix":"10.1016","volume":"78","author":[{"given":"Florence","family":"Joly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Hilpert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikou","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Stuart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasunori","family":"Ochiai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejca.2017.03.019_bib1","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamaoncol.2015.0530","article-title":"Patient-reported outcomes in cancer drug development and US regulatory review: perspectives from industry, the food and drug administration, and the patient","volume":"1","author":"Basch","year":"2015","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2017.03.019_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2014.08.004","article-title":"SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm","volume":"135","author":"Herzog","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.ejca.2017.03.019_bib3","doi-asserted-by":"crossref","first-page":"i66","DOI":"10.1093\/annonc\/mdw080","article-title":"Patient-reported outcomes (PRO) in ovarian cancer clinical trials-lost opportunities and lessons learned","volume":"27","author":"Friedlander","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2017.03.019_bib4","series-title":"Recommendations for incorporating Patient reported outcomes (PRO's) into clinical Comparative Effectiveness Research (CER) in Adult Oncology Published version 1.0 May 2012","author":"Effectiveness Guidance Document","year":"2012"},{"issue":"8","key":"10.1016\/j.ejca.2017.03.019_bib5","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.ejca.2017.03.019_bib6","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.ejca.2014.04.005","article-title":"Patient-reported outcomes in randomised controlled trials of gynaecological cancers: investigating methodological quality and impact on clinical decision-making","volume":"50","author":"Efficace","year":"2014","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2017.03.019_bib7","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1007\/s11136-016-1339-x","article-title":"The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols","volume":"25","author":"Mercieca-Bebber","year":"2016","journal-title":"Qual Life Res"},{"issue":"8","key":"10.1016\/j.ejca.2017.03.019_bib8","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","article-title":"A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)","volume":"26","author":"Cherny","year":"2015","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.ejca.2017.03.019_bib9","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1200\/JCO.2015.61.6706","article-title":"American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options","volume":"33","author":"Schnipper","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2017.03.019_bib10","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/IGC.0b013e3181dad379","article-title":"Assessing health-related quality of life in gynecologic oncology: a systematic review of questionnaires and their ability to detect clinically important differences and change","volume":"20","author":"Luckett","year":"2010","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2017.03.019_bib11","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"106","author":"Basch","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.ejca.2017.03.019_bib12","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","article-title":"Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial","volume":"15","author":"Pignata","year":"2014","journal-title":"Lancet Oncol"},{"issue":"Suppl. 10","key":"10.1016\/j.ejca.2017.03.019_bib13","doi-asserted-by":"crossref","first-page":"x64","DOI":"10.1093\/annonc\/mdt474","article-title":"Patient-reported outcomes in ovarian cancer clinical trials","volume":"24","author":"Friedlander","year":"2013","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2017.03.019_bib14","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/annonc\/mdr583","article-title":"Health-related quality of life in recurrent platinum-sensitive ovarian cancer\u2014results from the CALYPSO trial","volume":"23","author":"Brundage","year":"2012","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2017.03.019_bib15","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1007\/s00520-016-3297-9","article-title":"The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review","volume":"24","author":"Atkinson","year":"2016","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2017.03.019_bib16","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ygyno.2014.10.020","article-title":"A cost-utility analysis of NRG Oncology\/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer","volume":"136","author":"Cohn","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2017.03.019_bib17","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2165\/00019053-200422100-00002","article-title":"From randomised clinical trials to clinical practice: a pragmatic cost-effectiveness analysis of Paclitaxel in first-line therapy for advanced ovarian cancer","volume":"22","author":"Limat","year":"2004","journal-title":"Pharmacoeconomics"},{"issue":"23","key":"10.1016\/j.ejca.2017.03.019_bib18","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1002\/cncr.28940","article-title":"Patient preferences in advanced or recurrent ovarian cancer","volume":"120","author":"havrilesky","year":"2014","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2017.03.019_bib19","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ygyno.2016.10.021","article-title":"Treatment preferences of advanced ovarian cancer patients for adding bevacizumab to first-line therapy","volume":"143","author":"Lee","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2017.03.019_bib20","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1200\/JCO.2014.56.7974","article-title":"Statistical challenges in the analysis of health-related quality of life in cancer clinical trials","volume":"34","author":"Bonnetain","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9951","key":"10.1016\/j.ejca.2017.03.019_bib21","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2017.03.019_bib22","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/annonc\/mdw663","article-title":"5th Ovarian Cancer Consensus conference of the Gynecologic Cancer InterGroup: recurrent disease","volume":"28","author":"Wilson","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2017.03.019_bib23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/JCO.2012.44.4869","article-title":"Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4\/ACCORD 11 randomized trial","volume":"31","author":"Gourgou-Bourgade","year":"2013","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917308377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917308377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T05:22:25Z","timestamp":1601961745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917308377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":23,"alternative-id":["S0959804917308377"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.03.019","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}